Anticancer potential of benzo[b]thiophene functionalized thiosemicarbazone ligands and their organoruthenium complexes
Journal of Biological Inorganic Chemistry, cilt.30, sa.1, ss.71-85, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 30 Sayı: 1
- Basım Tarihi: 2025
- Doi Numarası: 10.1007/s00775-024-02090-w
- Dergi Adı: Journal of Biological Inorganic Chemistry
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE
- Sayfa Sayıları: ss.71-85
- Anahtar Kelimeler: Organoruthenium-arene complexes, Thiosemicarbazone, Anticarcinogenic activity, Ovarian cancer cell lines, Crystal structure
- Dokuz Eylül Üniversitesi Adresli: Evet
Özet
As novel promising anticancer candidates, the piano-stool type complexes of ruthenium, [RuCl(η6-p-cymene)(N,S-Ln)]PF6, K1-4, were synthesized from the reaction of the substituted benzo[b]thiophene based thiosemicarbazone ligands (L1-4) with [{RuCl(η6-p-cymene)}2(μ-Cl)2]. All complexes were fully characterized using elemental analysis, and spectroscopic methods such as FT-IR and 1H NMR. The molecular masses of the complexes were proved by MALDI-TOF analysis. Single crystal X-ray diffraction study was employed in the structural elucidation of complex K1 which shows a distorted octahedral geometry around the Ru(II) ion. Furthermore, spectroscopic methods revealed that in all complexes the ligands are coordinated to the metal center in neutral thione form via N, S donors. In this study, the effect of all ligands, complexes and commercial drugs with a different concentration on the viability of OVCAR-3, A2780 and OSE cells were compared. In this comparison, the cytotoxicity of ruthenium (II) complexes on two ovarian cancer cell lines (human A2780 and human OVCAR-3) was evaluated. For this purpose, the resazurin assay was performed. Based on our studies, complex K2 showed the highest toxicity against OVCAR-3 and A2780 cells. The cytotoxic effect of K2 was found to be higher than that of the commercial anticancer agents Oxalpin and Carbodex, 1.8–34.7-fold for OVCAR-3 cells and 1.9–11.8-fold for A2780 cells, respectively. These results provide insight into the potential of ruthenium (II) complexes as a cytotoxic agent for the treatment of ovarian cancer, particularly for primary tumors.